

2022 Key Accomplishments and Highlights

At Aurinia, we are a dedicated team of experts who are relentless in our pursuit to provide transformative medical treatments and bring value to shareholders, as well as healthcare providers and the patient community that we serve. Together, we are driven to make an impact for our patient communities as advocates and partners in innovation and for our employees by ensuring they have a sense of security, fulfillment, and purpose in their jobs and are fairly compensated.

We thank our shareholders for trusting us with their capital as we build a sustainable bio-pharmaceutical company. We encourage you to vote at our annual general meeting of shareholders and we thank you for your continued support.

-The Company drove significant growth in 2022, generating:

\$134.0 million in total net revenue, a 194% increase over the previous year

\$103.5 million in net product revenue, a 127% increase over the previous year

-At the close of 2022, Aurinia had with cash, cash equivalents, and investments of \$389.4 million, with no debt on our balance sheet.

-In July of 2022, LUPKYNIS received a positive CHMP opinion, based on a comprehensive submission including data from the pivotal AURORA 1 efficacy study and the AURORA 2 continuation study. Shortly thereafter, the European Commission granted marketing authorization in all EU member states as well as in Iceland, Liechtenstein, and Norway. Additionally, in September 2022 we were granted marketing authorization in Great Britain by the Medicines and Healthcare products Regulatory Agency.

-The LUPKYNIS launch has progressively improved, with \$40 million in net product revenue the truncated launch year and \$103.5 million in net product revenue in the second year

-Of the 28 drugs that launched in the United States during COVID, LUPKYNIS performed in top quartile through the fourth quarter of 2022

-There were approximately 1,525 patients on LUPKYNIS therapy as of December 31, 2022, compared with 870 at the end of December 31, 2021, an increase of greater than 75% year over year.

-Aurinia added a total of 1,648 Patient Start Forms (PSFs) during 2022 and has achieved a total of approximately 3,500 PSFs from launch to February 24, 2023.

-Since its launch in 2021, Aurinia Alliance has seen incredibly high average adherence rates of 85% for patients through the duration of participation in the program.

Thanks to strong leadership, resilience, and an ardent focus on operational and commercial execution, Aurinia is poised for continued growth in and outside the U.S., as we work to change the trajectory of autoimmune diseases with unmet needs.

